SPY303.53+4.45 1.49%
DIA255.77+5.52 2.21%
IXIC9,412.36+72.14 0.77%

Nektar Therapeutics Q1 EPS $(0.530) Beats $(0.710) Estimate, Sales $50.573M Beat $47.640M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.530) per share which beat the analyst consensus estimate of $(0.710) by 25.35 percent. This is a 22.06 percent increase over losses of $(0.680) per share

Benzinga · 05/07/2020 21:13

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.530) per share which beat the analyst consensus estimate of $(0.710) by 25.35 percent. This is a 22.06 percent increase over losses of $(0.680) per share from the same period last year. The company reported quarterly sales of $50.573 million which beat the analyst consensus estimate of $47.640 million by 6.16 percent. This is a 79.20 percent increase over sales of $28.222 million the same period last year.